Ginkgo Bioworks Partners with Inductive Bio and Tangible Scientific for AI-Driven Drug Discovery
Ginkgo Bioworks has announced a strategic partnership with Inductive Bio and Tangible Scientific to deploy AI-driven lab-in-the-loop workflows across the biopharma industry, announced in a press release. This collaboration aims to make AI-driven drug discovery more accessible by integrating high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a cohesive service.
The partnership leverages Ginkgo Datapoints' rapid ADME profiling, Inductive Bio's model-driven chemistry design platform, and Tangible Scientific's API-enabled compound management platform. This integration is designed to streamline the drug discovery process, reducing synthesis cycles and turnaround times while lowering overall costs.
By aligning design, experimentation, and data delivery into a single connected process, the partnership aims to enhance early-stage drug development efficiency. The services are now available for pharmaceutical and biotech teams seeking to improve ADMET optimization and reduce iteration times.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 30 Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354 Sep 29 Truven launches MarketScan Snapshot for healthcare data checks Sep 29 Omega Healthcare Wins Gold in 2026 AI Breakthrough Awards Sep 29 Phylo Launches Target Atlas for Drug Target Prioritization Sep 29 ChromAgeNet Detects Aging Signs in Blood Stem Cell ImagesLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Inductive Bio launches Beacon-2 to predict human drug doses
Domino Data Lab and EPAM Partner on Validated AI for Life Sciences
AbbVie Partners With Valkai on AI Tools for Clinical Development
Tsingke Introduces Validation Workflow for AI Designed Proteins
CAS and Novartis Partner on Reaction Data for AI Research
Daily AI Brief: the AI news that matters, in your inbox.